May 11, 2026 04:01PM
Mar 6, 2026 08:01AM
Mar 6, 2026 08:00AM
Feb 17, 2026 04:01PM
Jan 28, 2026 06:30AM
Dec 18, 2025 07:00AM
Dec 18, 2025 07:00AM U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Nov 17, 2025 11:21AM
Nov 7, 2025 08:31AM
Nov 7, 2025 08:30AM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 24, 2025 08:20AM
Sep 22, 2025 06:42AM Halozyme Therapeutics (HALO) PT Raised to $85 at H.C. Wainwright
Aug 5, 2025 04:01PM
May 28, 2025 08:31AM
May 28, 2025 08:30AM
May 6, 2025 04:01PM
Apr 10, 2025 06:15PM
Mar 31, 2025 08:31AM
Mar 31, 2025 08:30AM Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
Mar 6, 2025 06:53AM
Feb 18, 2025 04:01PM
Dec 30, 2024 06:55AM
Dec 30, 2024 06:31AM
Dec 30, 2024 06:30AM
Dec 18, 2024 06:47AM
Oct 31, 2024 04:01PM HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Oct 3, 2024 08:01AM
Oct 3, 2024 08:00AM
Sep 13, 2024 01:31PM
Sep 13, 2024 01:30PM
Sep 12, 2024 08:00PM
Aug 6, 2024 04:01PM
Jun 24, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Jun 21, 2024 05:15PM
May 21, 2024 07:16AM
May 21, 2024 07:15AM
May 7, 2024 04:01PM
Feb 20, 2024 04:01PM
Jan 29, 2024 04:15PM
Jan 16, 2024 08:17AM Halozyme (HALO) Announces Takeda (TAK) Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with CIDP
Jan 16, 2024 08:15AM
Nov 16, 2023 09:04AM
Nov 16, 2023 09:00AM
Nov 6, 2023 07:31AM
Nov 6, 2023 07:30AM
Aug 29, 2023 05:27AM
Aug 29, 2023 04:50AM Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
Aug 8, 2023 04:01PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All